Onychomycosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials By DelveInsight | Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Moberg Pharma, Sato Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Onychomycosis pipeline constitutes 11+ key companies continuously working towards developing 11+ Onychomycosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Onychomycosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Onychomycosis Market.

The Onychomycosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Onychomycosis Pipeline Report: https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Onychomycosis treatment therapies with a considerable amount of success over the years.
• Onychomycosis companies working in the treatment market are Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others, are developing therapies for the Onychomycosis treatment
• Emerging Onychomycosis therapies in the different phases of clinical trials are- MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail™, IDP-108, Itraconazole, and others are expected to have a significant impact on the Onychomycosis market in the coming years.
• Acquired by Pfizer, Anacor Pharmaceuticals Inc. has made notable advancements in the treatment of dermatophytic onychomycosis. Their topical antifungal product, Kerydin (tavaborole), is well-regarded for its effectiveness in treating onychomycosis.
• Johnson & Johnson, via its subsidiary Janssen Pharmaceuticals, plays a significant role in the dermatophytic onychomycosis treatment market. The company's focus on research and development has resulted in the development of effective antifungal treatments. Johnson & Johnson's extensive distribution network and strong brand reputation ensure their treatments are widely accessible.

Onychomycosis Overview
Onychomycosis is a fungal infection that affects the nails, typically the toenails but sometimes the fingernails as well. This condition, also known as tinea unguium, is caused by various types of fungi, including dermatophytes, yeasts, and non-dermatophyte molds.

Get a Free Sample PDF Report to know more about Onychomycosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Onychomycosis Drugs Under Different Phases of Clinical Development Include:
• MOB-015: Moberg Pharma
• BB2603: Blueberry Therapeutics
• HSG: Hallux
• Tavaborole: Pfizer
• MOB015B: Moberg Pharma AB
• P-3058: Polichem S.A.
• Organogel of naftifine: MediQuest Therapeutics
• Amorolfine: Repolar Ltd.
• TDT067 and Lamisil: Celtic Pharma
• Albaconazole: GlaxoSmithKline
• HTU-520: Hisamitsu Pharma
• P-3058: Polichem S.A.
• AN2690: Pfizer
• Efinaconazole: Bausch Health
• SUBA-itraconazole: Halcygen Pharma
• ME1111: Meiji Seika Pharma
• PD P 506 A: photonamic GmbH
• VT-1161: Viamet
• terbinafine: Novartis
• Luliconazole: Topica Pharma
• NVXT topical: Taro Pharma
• NB-002: NanoBio Crp
• HTS-519: Hallux, Inc.
• SCH 56592: Merck Sharp & Dohme
• Bifonazole cream 1%: Bayer
• EcoNail™: Abeona Therapeutics
• IDP-108: Dow Pharma
• Itraconazole: Taro Pharma

Onychomycosis Route of Administration
Onychomycosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Onychomycosis Molecule Type
Onychomycosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Onychomycosis Pipeline Therapeutics Assessment
• Onychomycosis Assessment by Product Type
• Onychomycosis By Stage and Product Type
• Onychomycosis Assessment by Route of Administration
• Onychomycosis By Stage and Route of Administration
• Onychomycosis Assessment by Molecule Type
• Onychomycosis by Stage and Molecule Type

DelveInsight's Onychomycosis Report covers around 11+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Onychomycosis product details are provided in the report. Download the Onychomycosis pipeline report to learn more about the emerging Onychomycosis therapies
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Onychomycosis Therapeutics Market include:
Key companies developing therapies for Onychomycosis are - Bausch Health Companies, Celtic Pharma, Galderma S.A., Johnson & Johnson, Anacor Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline Plc, Novartis AG, Topica Pharmaceuticals Inc., Bayer AG, Moberg Pharma AB, Allergen Inc., Cipla Ltd, Reddy's Laboratories Ltd, Sanofi S.A., Merz Pharma, Medimetriks Pharmaceuticals Inc., NovaBiotics Inc., ZimVie Inc., Wieland Dental, Teva Pharmaceutical Industries Ltd., Cardinal Health Inc., Zimmer Biomet, ZimVie Inc., Lumenis Ltd, Blueberry Therapeutics, Viatris Inc., Cardinal Health Inc., Valeant Pharmaceuticals International Inc., IMARC Group, Almirall S.A., and others.

Onychomycosis Pipeline Analysis:
The Onychomycosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Onychomycosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onychomycosis Treatment.
• Onychomycosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Onychomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Onychomycosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Onychomycosis drugs and therapies
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Onychomycosis Pipeline Strengths
• The introduction of novel, inexpensive, and non-invasive diagnostic technologies have led to rapid and accurate diagnosis of onychomycosis, hence increasing the rate of diagnosis.

Onychomycosis Pipeline Market Opportunities
• Current treatments have poor adherence and tolerability creating an opportunity for the key players to work on these areas

Scope of Onychomycosis Pipeline Drug Insight
• Coverage: Global
• Key Onychomycosis Companies: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others
• Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail™, IDP-108, Itraconazole, and others
• Onychomycosis Therapeutic Assessment: Onychomycosis current marketed and Onychomycosis emerging therapies
• Onychomycosis Market Dynamics: Onychomycosis market drivers and Onychomycosis market barriers

Request for Sample PDF Report for Onychomycosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Onychomycosis Report Introduction
2. Onychomycosis Executive Summary
3. Onychomycosis Overview
4. Onychomycosis- Analytical Perspective In-depth Commercial Assessment
5. Onychomycosis Pipeline Therapeutics
6. Onychomycosis Late Stage Products (Phase II/III)
7. Onychomycosis Mid Stage Products (Phase II)
8. Onychomycosis Early Stage Products (Phase I)
9. Onychomycosis Preclinical Stage Products
10. Onychomycosis Therapeutics Assessment
11. Onychomycosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Onychomycosis Key Companies
14. Onychomycosis Key Products
15. Onychomycosis Unmet Needs
16 . Onychomycosis Market Drivers and Barriers
17. Onychomycosis Future Perspectives and Conclusion
18. Onychomycosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Onychomycosis Epidemiology https://www.delveinsight.com/report-store/onychomycosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Onychomycosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Bacterial Vaginosis Market
https://www.delveinsight.com/report-store/bacterial-vaginosis-market
DelveInsight's comprehensive report titled "Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of bacterial vaginosis. The report presents historical and projected epidemiological data covering Total Prevalent Cases and Diagnosed Prevalent Cases of Bacterial vaginosis further segmented by Age.

Bile Duct Cancer Market
https://www.delveinsight.com/report-store/bile-duct-cancer-market
DelveInsight's "Bile Duct Cancer Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Bile Duct Cancer, historical and forecasted epidemiology as well as the Bile Duct Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.

Egfr-induced Skin Disorders Market
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market
DelveInsight's "EGFR Inhibitors-Induced Skin Disorders Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market
DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Endometrial Cancer, historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.

Fragile X Syndrome Market
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market
DelveInsight's "Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Fragile X Syndrome (FXS), historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.